AZN · Categories · Offerings
AZN - Public offerings
AstraZeneca PLC (AZN) public offerings - real-time wire coverage filtered to Offerings only.
Recent Offerings for AZN
- Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaCompletion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS) a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that, following clearance from the French Ministry of Economy and satisfaction of all other closing conditions, AstraZeneca (NASDAQ:AZN) completed the additional equity investment of $140M in Cellectis, as previously announced by Cellectis on November 1 and 15, 2023 (the "Additional Investment"). As part of the Additional Investment, AstraZeneca subscrib
- Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials– Proceeds will fund further development of AB248, a highly differentiated CD8-targeted IL-2 immunotherapy, through Phase 1b monotherapy expansion data, as well as initial safety and efficacy results from the ongoing combination with pembrolizumab – – Financing led by RA Capital Management with participation from existing investors and additional new investors, including AstraZeneca and Bristol Myers Squibb – Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of a Series C financing, which raised $55 million. The financing was led by RA Capital Management, and included
- Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZenecaExecution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously announced on November 1, 2023.Extraordinary shareholders' meeting of Cellectis to be held on or around December 22, 2023 to approve such investment. NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS) today anounced that, following the consultation of its works council, it has now signed a binding Subsequent Investment Agreement with AstraZeneca (NASDAQ:AZN) regarding the contemplated additional equity investment of $140M by AstraZeneca, which was previously announced on November 1, 2023. The additional investment will be made by w
- Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZenecaCollaboration leverages Cellectis' gene editing technologies and manufacturing capabilities to develop up to 10 novel cell & gene therapy candidate productsCellectis to receive up to $245M in cash (up to $220M equity investment and $25M upfront payment), with potential for additional milestones, plus tiered royalties NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS) today announced it has entered into (i) a Joint Research Collaboration Agreement (the "Collaboration Agreement"), (ii) an investment agreement relating to an initial equity investment of $80M, and (iii) a memorandum of understanding (the "MOU") relating to an additional equity investment of $140M, with AstraZ
- AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update– U.S. Commercial Launch Underway with Fully Deployed Sales Force Following FDA Approval of FOTIVDA® (tivozanib) on March 10, 2021 – – FOTIVDA Net Product Revenue of $1.1 Million from Initial Distributor Orders in the Last Week of Q1; All Distributors Have Placed Reorders for Q2 – – Entered Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb for Planned Pivotal Phase 3 TiNivo-2 Study of FOTIVDA in Combination with OPDIVO® (nivolumab); Study Anticipated to Commence Mid-2021 – – Phase 2 Open Label Randomized Study Results of Ficlatuzumab in HNSCC to be Presented at ASCO; Phase 3 Decision Anticipated Mid-2021 – – Company to Host Conference Call Today at 4:30 p.m. ET